# Entera Bio (ENTX) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/ENTX
## Company Profile
- Ticker: ENTX
- Exchange: NASDAQ
- Sector: Biopharma
- Location: Israel and listed in the U
- Tags: Biologics
## Stock Data
- Close: 3 USD
- Market cap: 61531651.25 USD
- Last updated: 2026-09-04
## Business Overview
### Oral Peptide Delivery
Entera Bio develops oral formulations of peptides and proteins that have traditionally required injection. Its proprietary N-Tab platform is designed to improve intestinal absorption in a convenient tablet form.
### EB613 Osteoporosis Program
EB613 is an oral parathyroid-hormone peptide candidate intended to provide anabolic, bone-building treatment for postmenopausal osteoporosis without daily injections.
### EB612 Hypoparathyroidism Program
EB612 is an oral long-acting PTH replacement candidate for hypoparathyroidism. It is being developed through an equal partnership with OPKO Health.
### EB618 Metabolic Program
EB618 is an oral oxyntomodulin candidate designed for dual GLP-1 and glucagon receptor activity in metabolic and fibrotic diseases, extending the platform beyond replacement therapies.
### Platform Business Model
Entera uses N-Tab both for internally controlled candidates and partnered programs, allowing the same delivery technology to support multiple peptide classes and therapeutic areas.
## Why The Stock Is Moving

As of Sep 4, 2026, ENTX closed up 1.69% at $3.00. No new same-company headline was identified in the current news window.

## Future Catalysts

- FDA feedback on the submitted Phase 3 protocol for EB613.
- IND submission for EB612 in late 2026.

## Recent News
- 2026-08-27 13:44 EST — [Correction: Entera to Participate in Upcoming Fall Investor Conferences](https://biopharmsignal.com/news/ENTX/correction-entera-to-participate-in-upcoming-fall-investor-conferences-83a14418) — Source: Entera Bio
- 2026-08-27 12:00 EST — [Entera to Participate in Upcoming Fall Investor Conferences](https://biopharmsignal.com/news/ENTX/entera-to-participate-in-upcoming-fall-investor-conferences-a4526155) — Source: Entera Bio
- 2026-08-18 12:00 EST — [Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., as Chief Medical Officer Ahead of Planned EB613 Phase 3 Initiation](https://biopharmsignal.com/news/ENTX/entera-appoints-global-pharmaceutical-leader-riccardo-paolo-camisasca-m-d-as-chi-f769885f) — Source: Entera Bio
- 2026-08-07 20:05 EST — [Entera Announces Second Quarter 2026 Financial Results and Business Updates](https://biopharmsignal.com/news/ENTX/entera-announces-second-quarter-2026-financial-results-and-business-updates-986e7094) — Source: Entera Bio
- 2026-08-04 12:30 EST — [Entera Bio Phase 2 Data Supporting EB613’s (Oral PTH(1-34)) Anabolic Effect on Postmenopausal Women with Osteoporosis at High Risk for Fracture Selected for Plenary Poster Session Presentation at the ASBMR 2026 Annual Meeting](https://biopharmsignal.com/news/ENTX/entera-bio-phase-2-data-supporting-eb613-s-oral-pth-1-34-anabolic-effect-on-post-5a471747) — Source: Entera Bio